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Abstract 
Background: Venom immunotherapy (VIT) is an effective treatment for subjects with systemic allergic reactions (SR) 
to Hymenoptera stings, however there are few studies concerning the relevance of the venom specific IgE changes to 
decide about VIT cessation. We assessed IgE changes during a 5-year VIT, in patients stung and protected within the 
first 3 years (SP 0–3) or in the last 2 years (SP 3–5), and in patients not stung (NoS), to evaluate possible correlations 
between IgE changes and clinical protection.
Methods: Yellow jacket venom (YJV)-allergic patients who completed 5 years of VIT were retrospectively evaluated. 
Baseline IgE levels and after the 3rd and the 5th year of VIT were determined; all patients were asked about field stings 
and SRs.
Results: A total of 232 YJV-allergic patients were included and divided into the following groups: 84 NoS, 72 SP 0–3 
and 76 SP 3–5. IgE levels decreased during VIT compared to baseline values (χ2 = 346.029, p < 0.001). Recent vespid 
stings accounted for significantly higher IgE levels despite clinical protection. IgE levels after 5 years of VIT correlated 
significantly with Mueller grade (F = 2.778, p = 0.012) and age (F = 6.672, p = 0.002). During follow-up from 1 to 
10 years after VIT discontinuation, 35.2 % of the contacted patients reported at least one field sting without SR.
Conclusions: The yellow jacket-VIT temporal stopping criterion of 5 years duration did not result in undetectable IgE 
levels, despite a long-lasting protection. A mean IgE decrease from 58 to 70 % was observed, and it was less marked in 
elderly patients or in subjects with higher Mueller grade SR.
Keywords: Hymenoptera venom allergy, Hymenoptera venom immunotherapy, Specific IgE levels, VIT long-lasting 
protection, VIT discontinuation
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Background
Venom immunotherapy (VIT) is an effective treatment 
for patients suffering from hymenoptera venom allergy 
(HVA) with severe systemic reaction (SR) and docu-
mented sensitization to the causative venom [1].
The optimal duration of VIT necessary to achieve long-
term protection has been evaluated in several studies, 
aimed to identify useful parameters for a safe stopping 
[2–4]. The initially identified criterion was the develop-
ment of negative skin tests and/or serum specific IgE 
(sIgE) tests [5]. However, it was later noted that such out-
come was rarely obtained, and that patients with positive 
sIgE were clinically protected from stings [2–6]. Thus, 
a VIT duration of at least 5 years was suggested, ideally 
accompanied by a decline in skin tests and sIgE levels 
[2–4, 7–11].
According to the latest guidelines, the decision to stop 
VIT must consider some risk factors for a future relapse, 
such as patient’s age, type of venom, severity of pre-VIT 
reaction, occurrence of SR during VIT, and likelihood of 
future stings [12, 13]. Thus, the physician may be reluc-
tant to stop VIT even when the temporal criterion is 
reached, because studies evaluating the relevance of the 
observed declines in sIgE to decide about VIT cessation 
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are scarce, especially regarding patients not stung during 
VIT, in whom the actual clinical protection is unknown.
In this study, we retrospectively evaluated the decrease 
in sIgE over 5 years of VIT in 3 groups of yellow jacket 
venom (YJV)-allergic patients: subjects stung and pro-
tected within the first 3  years or within the last 2  years 
of VIT, and patients not stung during the VIT course. 
Furthermore, we followed these three groups of patients 
regarding further field stings after VIT cessation, to 
assess the long-lasting protection of VIT and the occur-




For this retrospective study, we used our hospital data-
base and included YJV-allergic patients who completed 
5 years of VIT without SR due to venom injections at any 
point of VIT. All patients met the VIT admission crite-
ria and were treated in the Clinical Allergy and Immu-
nology Unit, Foundation IRCCS Ca’ Granda, Ospedale 
Maggiore Policlinico, Milan, Italy. Patients with elevated 
serum tryptase (>20 ng/mL) were excluded to avoid any 
mast cell disorder interference. Anamnesis were carefully 
documented, including the number of stings. SRs were 
classified according to Mueller grades [14].
All patients underwent VIT for at least 5  years with 
a maintenance dose of 100  μg of YJV (Vespula spp.) 
administered subcutaneously every 5  weeks, without 
changing the maintenance interval during the course of 
treatment. The VIT build-up phase was performed using 
a protocol that combines an initial rush session (first day 
0.01 + 0.1 + 1 + 3 μg, cumulative dose 4.11 μg) followed 
by weekly injections of 10, 20, 40, 70, 100 μg [15]. At the 
3rd and the 5th year of VIT, the patients underwent sub-
sequent diagnostic tests (skin tests and sIgE measure-
ments). The occurrence of field stings and the patient’s 
reaction were also documented.
The selected patients were divided into three groups: 
patients who were not stung (NoS) and patients who 
were stung and protected (SP) before the 3rd year (SP 
0–3) or between the 3rd and the 5th year of VIT (SP 
3–5); nobody among the SP patients experienced any SR 
after field stings.
Study design
The primary aims of the study were: (1) to evaluate the 
mean decrease in YJV-sIgE in all the patients and in 
patients stung in the first 3  years or in the last 2  years 
of VIT, and (2) to compare the mean YJV-sIgE decrease 
between patients stung and protected during VIT and 
patients not stung during VIT.
The secondary aims were: (1) to assess possible corre-
lations between decrease in sIgE and patients’ risk fac-
tors (age, reaction severity and number of stings), and (2) 
to assess the long-lasting protection in our patients by 
means of a phone follow-up.
Specific IgE level measurement
YJV-sIgE levels were measured in kUA/L by means of 
ImmunoCAP System (Phadia, Uppsala, Sweden) accord-
ing to the manufacturer’s instructions. Briefly, the aller-
gen of interest is covalently coupled to ImmunoCAP and 
reacts with the sIgE in the patient sample; after washing, 
enzyme-labeled antibodies against IgE are added. After 
incubation and washing of the unbound enzyme-labeled 
anti-IgE, the bound complex is incubated with a devel-
oping agent, and finally the fluorescence of the eluate is 
measured. The higher the response value, the more sIgE 
is present in the serum sample. The responses are trans-
formed into concentration by means of a calibration 
curve. The assay is highly automated and supplied of cali-
bration curve and control curve, with a calibrator range 
0–100  kUA/L. Clinical performance expressed as sensi-
tivity (84–95 %) and specificity (85–94 %) and stability of 
the results have been reported from previous multicen-
tric studies [16–18]. The tests were performed at baseline 
(CAP0) and after 3 (CAP3) and 5 (CAP5) years of VIT.
Statistical methods
We used: ANOVA analysis for repeated measures and 
the Wilcoxon post hoc test to evaluate the differences 
between the CAP values; ANOVA univariate analyses 
with the Bonferroni post hoc correction to evaluate the 
differences in each CAP value between the three groups; 
multivariate analysis for repeated measures (MANOVA) 
to evaluate the differences in the overall CAP values 
between the three groups as well as the effects of age, 
gender, Mueller grade and number of stings; Pearson’s 
index to evaluate the correlations between continuous 
variables; the exact non-parametric Wilcoxon test to 
evaluate variables on small samples. A p value <0.05 was 
considered statistically significant. Data were analyzed 
using the SPSS® program release 17.0 (SPSS Inc., Chi-
cago, IL).
Results
A total of 232 YJV-allergic patients (144 males, 88 
females; mean age 45.05 ±  15.48  years) who completed 
5 years of VIT were included in the study. Among them, 
84 patients (53 males, 31 females) were never stung dur-
ing VIT (group NoS), 72 patients (47 males, 25 females) 
were stung without SR by vespids within the first 3 years 
of VIT (group SP 0–3) and 76 patients (44 males, 32 
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females) were stung and protected during the last 2 years 
of VIT (group SP 3–5). No patient experienced SR dur-
ing VIT as a result of field stings or as an adverse reac-
tion to immunotherapy itself. The three groups had no 
statistically significant differences in mean age, number 
of stings before VIT or severity of sting reactions. The 
pre-VIT sting reactions were distributed as showed in 
Table 1. Considering other hypersensitivities, 22 patients 
had pollen allergies (11 NoS, 4 SP 0–3, 7 SP 3–5) and 17 
had drug hypersensitivities (5 NoS, 9 SP 0–3, 3 SP 3–5).
Evolution of IgE values during 5 years of VIT
For the whole cohort (n = 232), YJV-sIgE levels decreased 
during VIT (Fig. 1) (χ2 = 346.029, p < 0.001). This find-
ing was confirmed by post hoc tests (CAP0–CAP3: 
Z  =  −12.173, p  <  0.001; CAP3–CAP5: Z  =  −11.038, 
p < 0.001; CAP0–CAP5: Z = −12.850, p < 0.001).
CAP5 and CAP3 were significantly different among 
the three groups, whereas no significant differences were 
found between the three groups at baseline (Table 2).
The overall percentage reduction in CAP at the first 
(3rd year) and last (5th year) control were 44.2 and 
34  %, respectively; the mean CAP percentage decrease 
between the baseline and the 5th year control reached 
65.6  %, unlike the statistical analysis performed on skin 
test results that did not detect any significant differences 
(data not shown).
Considering CAP3 values, NoS patients had YJV-sIgE 
levels significantly lower than SP 0–3 patients; those who 
had experienced a more recent sting (SP 0–3) showed 
significantly higher CAP values than patients who were 
not stung (NoS). No significant difference was found 
between NoS and SP 3–5 patients, and between SP 0–3 
and SP 3–5 (Table  2). The patients who were not stung 
during the first 3 years of VIT (NoS and SP 3–5) showed 
similar mean percentage reductions in CAP values, 48.2 
and 53.7  %, respectively, while the reduction of the SP 
0–3 patients was only 30.7 % (Table 3).
At the final VIT control (CAP5), the patients who were 
recently stung (SP 3–5) had significantly higher CAP 
values than those who were not stung or were stung 
during the first 3  years of VIT (Table  2). The sIgE final 
percentage reduction in the SP 3–5 group was less than 
60 % when compared to baseline, while NoS and SP 0–3 
patients presented a reduction of approximately 70  % 
(Table 3).
Influence of risk factors on the evolution of sIgE values
MANOVA analysis revealed that the CAP values were 
different during VIT (F =  28.872, p  <  0.001) in the dif-
ferent groups (NoS, SP 0–3, SP 3–5). CAP values were 
also significantly related to Mueller grade (F  =  2.778, 
p = 0.012) and age (F = 6.672, p = 0.002): a higher Muel-
ler grade and a more advanced age were associated with 
higher CAP5 values. The Pearson’s index confirmed a 
significant correlation between age and CAP 0–5 reduc-
tion (r = −0.609, p  <  0.001). The other analyzed varia-
bles (gender and number of stings) were not statistically 
significant.
Follow‑up after VIT discontinuation
All the patients were contacted by phone to determine 
if they had been stung after VIT cessation; results are 
reported in Table  4. We successfully contacted 159/232 
(68.5  %) patients. Among the 84 NoS patients, we suc-
cessfully contacted 70 (83  %) patients, 13 of which had 
been field-stung. 21 of the SP 0–3 patients and 22 of 
the SP 3–5 patients had been field-stung. A total of 56 
(35.2 %) patients reported at least one field sting without 
any systemic reaction, from 1 to 10 years after VIT cessa-
tion. Some patients received multiple vespid stings from 
several months to several years after VIT cessation and 
did not experience any reactions.
Despite the clinicians recommendations to come back 
to our Centre for sIgE level determination in case of 
field sting after VIT discontinuation, only 13/56 (23.2 %) 
patients did. These patients (eight males, five females; 
mean age 43.54 ± 17.55) had a well tolerated field sting 
from few months to 4  years after VIT stopping. All of 
them had already been field stung during VIT, as seven 
patients belonged to SP 0–3 group and six to SP 3–5 
group. As shown in Fig. 2, the mean IgE level determined 
about 2  months after the field sting resulted signifi-
cantly different from the IgE level at baseline (Z = 2.342; 
p  =  0.016) and at 5th year control (Z  =  −2.118; 
p = 0.034), while it did not differ from 3rd year control 
(Z = −0.235; p = 0.850).
Discussion
In this retrospective study, we selected 232 YJV-allergic 
patients. Serum sIgE levels determined before starting 
VIT, and at 3rd and 5th year controls, showed a signifi-
cant decrease over time, which was an expected result. In 
fact, one of the immunological effects of VIT is the pro-
gressive reduction of sIgE levels [6, 19–21]. The reduction 
Table 1 Patients’ Mueller grade reaction
Mueller grade reaction of our total study population, divided in patients never 
stung (NoS), stung in the first 3 years (SP 0–3), and stung in the last 2 years (SP 
3–5) of venom immunotherapy
Mueller I Mueller II Mueller III Mueller IV
NoS 9 16 33 26
SP 0–3 8 18 25 21
SP 3–5 8 21 26 21
Total 25 55 84 68
Page 4 of 8Pravettoni et al. Clin Mol Allergy  (2015) 13:29 
Fig. 1 Decreases of IgE levels during VIT. Decreases in sIgE levels over 5 years of VIT in three groups of YJ-allergic patients (NoS not stung, SP 0–3 
stung and protected within the first 3 years of VIT, SP 3–5 stung and protected in the last 2 years of VIT)
Table 2 Statistical results of IgE variations during VIT
Statistically significant P values are in italics
Mean CAP values (±standard deviation) by group (NoS not stung, SP 0–3, stung and protected within the first 3 years of VIT, SP 3–5 stung and protected in the last 
2 years of VIT) and results of statistical analysis
YJ‑IgE levels 
(kUA/L)
Group ANOVA Post‑Hoc test
NoS vs SP 0–3 NoS vs SP 3–5 SP 0–3 vs SP 3–5
NoS SP 0–3 SP 3–5 F P P P P
(95 % CI) (95 % CI) (95 % CI)
CAP0 5.34 ± 6.26 6.27 ± 6.81 7.27 ± 7.05 1.663 0.192 1.00 (−3.53; 1.66) 0.209 (−4.49; 0.62) 1.00 (−3.65; 1.66)
CAP3 1.91 ± 2.42 3.81 ± 4.62 2.59 ± 2.80 6.261 0.002 0.002 (−3.20; −0.59) 0.616 (−1.96; 0.61) 0.085 (−0.11; 2.55)
CAP5 0.97 ± 1.44 1.15 ± 1.17 2.13 ± 3.11 6.948 0.001 1.00 (−0.98; 0.63) 0.002 (−1.95; −0.36) 0.014 (−1.81; −0.16)
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of venom sIgE during VIT is a well known effect since 
1983, when the loss of venom sensitivity due to VIT was 
described, with IgE levels showing an initial increase, and 
then followed by a reduction over the 3 years of VIT [6, 
22]. The sIgE reduction over the course of VIT was con-
firmed by many studies, performed with both children 
and adults: after an initial increase at maintenance dose, 
venom sIgE fall after 3–5 years of venom immunotherapy 
[19–24]. Some Authors found a small decline in the mean 
venom sIgE levels also during the first year after VIT 
was stopped, suggesting both the duration of 5-year VIT 
and the passage of time can play a role in the decrease 
of sIgE [19]. The mechanism of specific IgE reduction 
during immunotherapy is likely due to the cytokine shift 
from a T-helper 2 to a T-helper 1 dominant pattern [25, 
26]. Changes in cytokine production (decrease of IL-4, 
increase of IFN-gamma and IL-10) has been demon-
strated for VIT, also during the early phase, with poten-
tial down regulation of mast cell and basophil reactivity, 
and rapid desensitization in rush VIT; in the longer term, 
the immunological shift would result in an isotype switch 
from IgE to IgG [27–29].
Studies on natural history of insect sting allergy showed 
that, among patients with SRs and positive skin tests not 
treated with VIT, about 60  % had clinical re-sting reac-
tions, with an higher rate of reactions in patients with 
more severe initial reactions [30]. Golden et al. [31] eval-
uated the changes in diagnostic tests and the risk of sting 
reactions in patients not admitted to VIT, demonstrat-
ing a 10–12 % per year loss in skin test positivity, with a 
negativization in 45 % of subjects after 4 years. Sensitiza-
tion to venom may disappear in 30–50  % of cases after 
5–10 years, but can also persist for many years even with-
out sting exposure, with a 20 % chance of systemic reac-
tion after 15  years in subject not treated with VIT. The 
risk of future systemic reactions depends on the severity 
Table 3 IgE percentage reduction during VIT related to field sting
Absolute (mean ± standard deviation SD, minimum and maximum) and percentage reductions of CAP values by group (NoS not stung, SP 0–3 stung and protected 
within the first 3 years of VIT, SP 3–5 stung and protected in the last 2 years of VIT)
YJ‑IgE levels (kUA/L) Group Mean ± SD Min Max Mean percentage 
reduction (%)
CAP0–CAP3 NoS 3.81 ± 5.13 0.01 27.59 48.2
SP 0–3 2.61 ± 3.53 0.00 21.22 30.7
SP 3–5 4.75 ± 5.32 0.00 25.07 53.7
CAP3–CAP5 NoS 0.97 ± 1.60 0.00 11.97 37.1
SP 0–3 2.68 ± 4.13 0.00 20.97 50.3
SP 3–5 0.82 ± 1.03 0.00 6.40 17.0
CAP0–CAP5 NoS 4.39 ± 5.48 0.00 27.54 68.6
SP 0–3 5.15 ± 6.16 0.00 30.87 70.5
SP 3–5 5.24 ± 5.55 0.12 25.30 57.7
Table 4 VIT discontinuation: restung patients’ follow-up
Follow-up after VIT discontinuation: number of patients stung and protected 
(SP) after stopping by group and period of time
a At least one patient received other field stings before or after
Patients NoS during VIT SP during VIT
Total 84 148
Recalled 70 89
SP after VIT stopping 13/70 43/89
 Within 1 year after 2 16a
 After 2–3 years – 11a
 After 4–5 years 6 5a
 After 7–8 years 3a 7 (4; 3a)
 After 9–10 years 2 4 (1; 3a)
Fig. 2 IgE levels after field sting and VIT discontinuation. Mean 
IgE levels in 13 patients at a field sting after VIT stopping related to 
their mean IgE levels during VIT (grey part). After field sting IgE levels 
increased and returned to the levels of the intermediate control 
(CAP3), independently from the period of field sting during VIT and 
from the time between VIT stopping and field sting
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of previous reactions: it is higher (60–70 %) in adults with 
severe anaphylaxis than in those with moderate (40 %) or 
mild (20 %) anaphylaxis [32]. In these studies, the reac-
tivity of patients was assessed by spontaneous field stings 
or by deliberate sting challenges. Each method has its 
limitations: for field sting there is the uncertainty of the 
insect identification, for sting challenge (at least concern-
ing vespids) there is the uncertainty of the amount of 
venom [33]. Indeed, there are studies demonstrating that 
a single negative sting challenge is not decisive to predict 
patient protection [33–35]. Up to now, in many European 
Countries, including Italy, the sting challenge is not rec-
ommended because is considered poorly reproducible 
and hazardous [12]. In one of the first surveys on VIT 
[6], 71 % of patients were clinically protected after a field 
sting, even though only a minority of them had negative 
sIgE after 3 years of VIT. Golden found a similar low per-
centage (approximately 30 %) of skin test negativization 
after 5 years of VIT, though all patients were sting chal-
lenge negative [36]. In the present study, at VIT cessation 
none of our patients exhibited a complete negativization 
of YJV-sIgE, even though the majority of them (63.8 %) 
had at least one well tolerated vespid field sting. Hence, a 
correlation between clinical protection and negativity of 
sIgE may not exist and should not be considered a reli-
able indicator of successful VIT.
To our knowledge, this is the first study investigat-
ing the associations of the risk factors for relapse after 
VIT with the evolution of sIgE levels during VIT. In our 
elderly patients and in patients with higher Mueller grade 
reactions, we observed a smaller decrease in sIgE during 
the VIT course; our results correlate well with the previ-
ously published data [7, 8, 11, 15]. A clinician evaluating 
the decision to stop VIT could take into consideration 
that patients with higher Mueller grade reactions and 
advanced age could present a smaller decrease of venom-
sIgE, without necessarily invalidating the efficacy of VIT.
Analyzing the sIgE levels over time and the differ-
ences between the three groups (NoS, SP 0–3 and SP 
3–5), we found a significant difference in CAP values at 
the 3rd year control between NoS and SP 0–3 patients, 
because of the sIgE increase associated to the recent 
vespid sting in the latter group. There was no significant 
difference between SP 0–3 and SP 3–5 patients, though 
the first group experienced a recent vespid sting, prob-
ably because of the higher CAP0 value presented by SP 
3–5 patients. NoS and SP 3–5 patients exhibited a mean 
percentage reduction between CAP0 and CAP3 values 
of approximately 50 %, while SP 0–3 patients exhibited a 
less marked decrease (30 %).
At the 5th year control SP 0–3 patients had reduced 
CAP values, that were comparable with those of NoS 
patients. There was a significant difference between NoS, 
SP 0–3 and SP 3–5 patients. Considering the mean per-
centage reduction between CAP3 and CAP5, SP 3–5 
patients achieved only a 17 % reduction, while NoS and 
SP 0–3 patients experienced reductions of 37 and 50 %, 
respectively. Therefore, subjects who experienced a 
recent vespid sting, even if clinically protected, had sig-
nificantly higher CAP values than patients who were not 
recently stung. Hence, higher than expected mean CAP 
values after 5 years of treatment in patients with recent 
field stings should not be considered as a criterion for 
VIT continuation. Despite sIgE levels has been evalu-
ated after some years, we consider our CAP results to be 
reliable, as the stability, the reproducibility and the high 
degree of standardization of the ImmunoCAP assay have 
been previously demonstrated, retesting the same serum 
sample after storage at −20 °C over an 8-year period and 
confirming the reproducibility of the quantitative meas-
urements of sIgE [18]. Furthermore, the coefficient of 
variation of the assay is very low (≤10 %) and independ-
ent of allergen specificity and IgE levels [37]. In our study 
the overall variability of sIgE detection at 3rd and 5th 
year of VIT is higher than 10 % of the coefficient of varia-
tion, so we can state that a real decrease in sIgE detection 
occurred.
After VIT stopping, 13 patients (seven belonging to SP 
0–3 group and six to SP 3–5 group) underwent labora-
tory analyses after field stings. In this few patients sIgE 
levels increased after the field sting, resulting similar to 
the 3rd year control (Fig. 2).
We also performed phone interviews, asking patients if 
they had been stung after VIT stopping, to evaluate the 
protection rate. Among the 159 responders (70 NoS and 
85 SP), 56 (35.2 %) reported one or more well-tolerated 
stings; almost all patients were clinically protected until 
3 years after VIT cessation, and some were protected up 
to 10  years post-VIT. Only 19  % of NoS patients were 
stung after VIT termination; SP patients received more 
field stings than NoS patients after stopping VIT, most 
likely because they were less fearful to expose to risky 
outdoors situations. The follow-up survey after VIT ces-
sation determined that all recalled patients, after 5 years 
VIT, were clinically protected for up to 10 years.
Considering the percentage reductions after 5 years of 
VIT, we observed that patients stung or not stung dur-
ing the first 3  years showed a mean CAP reductions of 
roughly 70  % compared to their baseline values. For 
patients who were stung within the last 2  years of VIT, 
the mean CAP value decreased by roughly 58  % com-
pared to baseline.
Conclusions
In conclusion, when a patient fulfills the temporal cri-
terion for VIT duration (at least 5  years) but still has 
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positive sIgE tests, a mean IgE decrease ranging from 58 
to 70 % compared to baseline is likely to be expected. This 
decrease could be less striking in elderly patients or in 
subjects with a higher pre-treatment Mueller grade SR. 
Anyhow, the measurement of venom-specific IgE levels 
remains the best in  vitro parameter to monitor VIT, as 
demonstrated by follow-up studies of patients with long-
lasting protection.
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